Skip to content
ENT SurgicalTech & Protocols

Non-Energy Dissection with IONM for RLN Protection in Thoracoscopic Lung Cancer Resection

Combining non-energy instruments with intraoperative RLN monitoring cut vocal cord paralysis from 17.2% to 7.5% and improved recovery in thoracoscopic NSCLC resection.

IP

Editorial Team

Clinical evidence review

7 min read
Source:Journal of Cancer Control and Treatment (2023)DOI10.3969/j.issn.1674-0904.2023.09.010

Key Takeaways

  • Combining non-energy dissection instruments with Intraoperative Neurophysiological Monitoring (IONM) reduced Recurrent Laryngeal Nerve (RLN) injury from 17.17% to 7.48% (χ² = 4.533, P = 0.033) during single-port thoracoscopic lobectomy with RLN-related lymph node dissection.
  • All monitored patients with RLN injury recovered within 12 months (100% vs 47.06%, P = 0.022), with half recovering within the first postoperative month.
  • Independent risk factors for RLN injury included BMI (OR = 1.228, 95% CI: 1.030–1.465, P = 0.022), central tumor location (OR = 0.079, 95% CI: 0.022–0.285, P < 0.001), left-sided primary tumor (OR = 3.613, 95% CI: 1.130–11.550, P = 0.030), and use of energy devices (OR = 5.237, 95% CI: 1.686–16.266, P = 0.004).
  • The overall metastasis rate of RLN-related lymph nodes was 6.96% (38/546), confirming that stations 2R, 3p, 4L, and 5 cannot be routinely omitted from oncologic dissection.

Clinical Context

Mediastinal lymph node dissection is a prerequisite for curative resection and accurate staging in non-small cell lung cancer (NSCLC), and the number of resected nodes is an independent prognostic factor. However, dissection of the RLN-related nodal stations—2R, 3p, 4L, and 5—carries a well-documented risk of RLN injury, leading to Vocal Cord Paralysis (VCP), aspiration, and pulmonary infection. Nearly all inadvertent RLN injuries during thoracic oncology procedures are associated with mediastinal lymph node dissection, and vocal cord dysfunction has been reported in up to 31% of patients after left lung resection for cancer.

Two mechanisms dominate RLN morbidity in this setting. First, thermal injury: thermal energy devices can generate temperatures exceeding 100 °C, well above the ~60 °C threshold for irreversible nerve damage, and thermal spread can injure the nerve even without direct contact. Second, failure of nerve identification: up to 68% of left-sided RLN injuries stem from the surgeon's inability to recognize the nerve, particularly when it is embedded in dense connective tissue or distorted by enlarged nodes.

IONM—long established in thyroid and esophageal surgery—offers real-time functional verification of the RLN and Vagus Nerve (VN). This retrospective cohort from a high-volume tertiary thoracic surgery center (First People's Hospital of Neijiang, 2020–2022) tested whether pairing IONM with non-energy dissection (tissue scissors, endoscopic scissors, and dissection forceps) could reduce RLN injury during single-port video-assisted thoracoscopic surgery (VATS).

Clinical Evidence & Cohort Breakdown

A total of 206 patients with NSCLC (T1–3N0–2M0) undergoing single-port thoracoscopic anatomic lobectomy with systematic lymphadenectomy were allocated to the NE-RLNM group (non-energy devices + IONM, n = 107) or the Energy group (energy devices, n = 99). All patients had preoperative laryngoscopy confirming intact vocal cord function. Baseline characteristics—age, sex, smoking, BMI, FEV1, tumor location, lobar distribution, diameter, stage, and histology—were balanced between groups (all P > 0.05).

Outcome NE-RLNM Group (n = 107) Energy Group (n = 99) Statistic P
Operative time, min [M(Q)] 150 (25.00) 140 (35.00) Z = −3.071 0.002
Blood loss, mL [M(Q)] 150 (100.00) 100 (150.00) Z = −0.441 0.659
Conversion to open surgery, n (%) 8 (7.48%) 5 (5.05%) χ² = 0.512 0.474
Chest tube drainage POD1, mL [M(Q)] 210 (140.00) 170 (150.00) Z = −2.017 0.044
Duration of tube use, days [M(Q)] 5 (3.00) 6 (3.00) Z = −0.585 0.559
RLN injury, n (%) 8 (7.48%) 17 (17.17%) χ² = 4.533 0.033

RLN-related lymph node metastasis (n = 546 nodes dissected):

Station Metastatic Nodes (n) Dissected Nodes (n) Metastasis Rate
2R 13 161 8.07% (13/161)
3p 5 115 4.35% (5/115)
4L 9 125 7.20% (9/125)
5 11 145 7.59% (11/145)
Total 38 546 6.96% (38/546)

Recovery from RLN injury (1-year follow-up):

Recovery Timepoint NE-RLNM Group (n = 8) Energy Group (n = 17) P
1 month 4 (50.00%) 3 (17.65%) 1.000
3 months 2 (25.00%) 3 (17.65%) 1.000
6 months 1 (12.50%) 1 (5.88%) 1.000
12 months 1 (12.50%) 1 (5.88%) 1.000
Total recovered 8 (100.00%) 8 (47.06%) 0.022

No perioperative deaths or severe complications occurred. The NE-RLNM group required modestly longer operative time and had higher POD1 drainage—attributed to the time cost of nerve mapping, frequent instrument exchange, and small lymphatic leaks from non-energy nodal separation that are not sealed by coagulation.

Intraoperative IONM Protocol & Technical Pearls

The following workflow reflects the protocol used in the monitored cohort, adapted to standard international IONM practice for thoracic RLN dissection:

  1. Anesthesia setup. Standard general anesthesia; avoid non-depolarizing neuromuscular blockers after induction to prevent Neuromuscular Blockade (NMB) Residual from suppressing EMG responses. Use a bronchial blocker rather than a double-lumen Endotracheal Tube (ETT) to preserve single-lung ventilation while keeping the airway available for an EMG Endotracheal Tube (EMG Tube).
  2. Electrode placement. Position a Medtronic NIM 3.0 EMG Tube with two recording electrodes so that they contact both vocal cords. Place Subdermal Needle Electrodes near the xiphoid process, at least 2 cm apart, as the reference/monitoring pair.
  3. Stimulation parameters. Introduce a Monopolar Stimulating Probe through the surgical port into the thoracic cavity. Use direct-current stimulation of 0.5–3.0 mA at 4 Hz, with an event threshold of 100 μV. Confirm nerve identity by evaluating both EMG Amplitude (μV) and Latency (ms).
  4. Baseline VN mapping. Before dissection, stimulate the VN to obtain a baseline EMG signal (V1). Follow the VN distally to locate the RLN origin and obtain an RLN signal (R1), then mark the approximate nerve course on the surgical field.
  5. Branch identification. Expose both the motor and sensory branches of the RLN. Prioritize protection of the motor branch; a sensory branch may be divided if needed to access deep nodal tissue.
  6. In-situ dissection. Perform dissection in situ with tissue scissors, endoscopic scissors, and dissection forceps, minimizing mechanical traction. When encountering ambiguous tissue, stimulate it: an audible alarm with a displayed waveform (R2) confirms the RLN is adjacent and must be preserved; absence of signal permits safe division.
  7. Energy-device discipline (if used). When electrocautery is required, keep the active tip at least 0.5 cm from the RLN motor branch and divide vascularized nodal pedicles in "Coag" mode (energy level 55). Never activate energy devices in direct contact with or in close proximity to the nerve.
  8. Completion check (V2/R2). After nodal clearance, re-stimulate the RLN and VN to confirm signal integrity. A Loss of Signal (LOS) mandates review of the surgical field for Traction Injury or Thermal Injury and documentation of the event.

Clinical Implications for Surgeons & IONM Specialists

  • Non-energy dissection plus IONM is a feasible, safe strategy for RLN-related nodal stations in single-port VATS, halving the RLN injury rate relative to energy-based dissection. The trade-off is a modest increase in operative time (~10 min) and POD1 drainage, which did not translate into longer chest tube duration or higher conversion rates.
  • Recovery profile favors monitored non-energy dissection. Every injured patient in the monitored group recovered within one year, versus fewer than half in the energy group—consistent with the principle that Traction Injury and compression are typically transient, whereas Thermal Injury and transection are frequently permanent. The absence of permanent VCP in the monitored cohort is clinically meaningful.
  • Risk stratification should guide aggressiveness. Patients with BMI ≥ 24 (injury rate 18.31% vs 8.89% for BMI < 24), central tumors, and left-sided primaries carry higher risk; these are non-modifiable factors, making technique selection and IONM the primary levers for harm reduction. Left-sided dissection deserves particular vigilance given the longer intrathoracic RLN course and its susceptibility to distortion by adenopathy.
  • Oncologic adequacy is preserved. Station-specific metastasis rates of 4.35%–8.07% confirm that RLN-related nodes are genuine drainage basins and should not be abandoned; IONM enables thorough clearance without sacrificing nerve function.
  • Limitations to acknowledge. This is a retrospective single-center study with a small number of injury events, precluding demonstration of a statistically significant difference in recovery time. Monitoring data were not captured in a standardized four-step (V1, R1, R2, V2) format, and False-Positive LOS / True-Positive LOS rates could not be analyzed. Prospective controlled trials with standardized Continuous IONM (C-IONM) or Intermittent IONM (I-IONM) documentation are warranted.

Reference

Liu CY, Ran R, Li XL, Luo L, Shao H, Liu GH, Wang Y, Li J. Application of non-energy devices and recurrent laryngeal nerve monitoring in recurrent laryngeal nerve protection during thoracoscopic radical resection of lung cancer. Journal of Cancer Control and Treatment. 2023;36(9):778–786. doi:10.3969/j.issn.1674-0904.2023.09.010

Medical Disclaimer: This article is provided for informational and educational purposes only and does not constitute medical advice. Clinical decisions regarding surgical technique, IONM protocols, and patient management should be made by qualified healthcare professionals based on individual patient circumstances and institutional guidelines.

Medical disclaimer

This protocol is provided for clinical education and reference only. It does not constitute medical advice, a standard of care, or a substitute for surgeon judgment, institutional policy, device labeling, or patient-specific assessment. Verify all stimulation parameters, electrode compatibility and indications against current manufacturer instructions before use. Read the full disclaimer.

Continue the protocol

Related guidance

View the IONM library